Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, targeted therapies, and surgery techniques.

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of pelareorep, an investigational oncolytic virus ...

Esophageal and stomach cancers begin in different parts of the gastrointestinal tract, but they share certain risk factors, treatment options, and more.

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

Dysphagia is a common early symptom of esophageal cancer, often confused with digestive issues, delaying diagnosis. Treatment varies by cancer stage; early-stage often involves surgery and ...

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma ...

Esophageal cancer affects the esophagus lining, causing swallowing difficulty and chest pain. Learn what symptoms to look for, and how you can treat and prevent esophageal cancer.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...